* The Medicines Co., of Cambridge, Mass., purchased worldwide rights to IS-159, a highly selective agonist to the 5-hydroxytriptamine receptors, which are found on blood vessels and nerve terminals in the brain. The drug, a triptan-like compound was acquired from Immunotech S.A., of Marseilles, France. IS-159 is in Phase II studies in Europe for the treatment of acute migraine headache. Immunotech is a subsidiary of Beckman Coulter Inc.